May 11, 2020 / 6:31 AM / in 17 days

BRIEF-Astrazeneca Says Lynparza Gets Broader U.S. Ovarian Cancer Approval

May 11 (Reuters) - AstraZeneca PLC:

* LYNPARZA GETS BROADER US OVARIAN CANCER APPROVAL

* LYNPARZA APPROVED IN US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB FOR HRD-POSITIVE ADVANCED OVARIAN CANCER

* APPROVAL BY US FOOD AND DRUG ADMINISTRATION (FDA) WAS BASED ON A BIOMARKER SUBGROUP ANALYSIS OF PHASE III PAOLA-1 TRIAL

*

* PATIENTS TREATED WITH LYNPARZA & BEVACIZUMAB LIVED WITHOUT DISEASE PROGRESSION FOR 37.2 MONTHS VERSUS. 17.7 MONTHS MEDIAN FOR BEVACIZUMAB

* FOLLOWING THIS APPROVAL FOR LYNPARZA IN US, ASTRAZENECA WILL RECEIVE FROM MSD $100M IN COLLABORATION REVENUE

* LYNPARZA GETS BROADER US OVARIAN CANCER APPROVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below